GEHC · NasdaqGS
Medical Devices · United States
Snapshot 2026-11-11 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Company websiteQ3 2026
Published 2026-11-11
Short takes Q3 2026
GEHC Stock: GE HealthCare Q3 2026 — The Cash Test #Shorts
Watch Short on YouTube
Q3 2026 REPORT HIGHLIGHTS
GE HealthCare expanded margins across all segments and raised guidance; our $80 HOLD valuation tests recurring cash, tariff refunds and acquisition demands.
Adjusted EBIT margin rose to 16.6%, with improvement across all three segments.
Segment EBIT reached $68M after the Q2 loss; sustained recovery remains the test.
Q3 FCF was $793M, including $55M of cash tariff refunds; the two figures are not equivalent.
Adjusted EPS is now $4.95–$5.05 and free cash flow is expected above $1.6B.
Intelerad cost $2.293B; SOFIE is a separate pending $945M transaction. Our current value is $80.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | GEHCGE HealthCare Technologies Inc.Snapshot 2026-11-11Financial period: 2026-09-30 |
|---|---|
| Market capMarket value, converted to USD | US$37.35B |
| Forward P/EProvider forward earnings estimate | 15.01x |
| EV / EBITDAEnterprise value / trailing EBITDA | 12.69x |
| Revenue growthLatest quarter vs prior-year quarter | 7.2% |
| Operating marginLatest reported quarter | 13.8% |
| Free cash flow yieldTrailing cash flow / market cap | 4.9% |
| Net debt / EBITDANet debt / trailing EBITDA | 2.11x |
| Debt / equityTotal debt / positive book equity | 0.88x |
| Trailing P/ETrailing twelve-month earnings | 17.46x |
| Price / bookPrice / positive book equity per share | 3.22x |
| EV / salesEnterprise value / trailing revenue | 2.11x |
| Earnings growthLatest quarter vs prior-year quarter | 39.0% |
| Gross marginTrailing twelve months | 39.3% |
| Net marginTrailing twelve months | 10.0% |
| Return on equityProvider trailing return; positive equity only | 20.0% |
| Free cash flow marginTrailing free cash flow / revenue | 8.5% |
| Dividend yieldIndicated annual dividend / price | 0.2% |
| Earnings payoutProvider trailing dividend payout | 3.0% |
| Current ratioCurrent assets / current liabilities | 1.30x |
| BetaProvider historical market sensitivity | 0.77 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q3 2026
GE HealthCare expanded margins across all segments and raised guidance; our $80 HOLD valuation tests recurring cash, tariff refunds and acquisition demands.
Research published November 10, 2026 · Download original report
Read Research PacketPresentation · 2026-11-11 · YouTube
Short takes Q3 2026
GEHC Stock: GE HealthCare Q3 2026 — The Cash Test #Shorts
Watch Short on YouTube
Presentation · 2026-07-30 · YouTube
Short takes Q2 2026
GEHC: Record Orders, Shrinking Margin
Watch Short on YouTube
Presentation · 2026-04-29 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
